RAM
ALGS icon

Readystate Asset Management’s Aligos Therapeutics ALGS Stock Holding History

Readystate Asset Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-203,113
Closed -$1.99M – 389
2025
Q3 		$1.99M Buy
203,113
+66,331
+48% +$606K 0.08% 149
2025
Q2 		$986K Buy
136,782
+91,382
+201% +$547K 0.03% 212
2025
Q1 		$375K Buy
+45,400
New +$995K 0.01% 507

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Readystate Asset Management's ALGS Position: Q4 2025 in Review

Readystate Asset Management sold out of Aligos Therapeutics (ALGS) in Q4 2025, closing a stake of 203,113 shares — an estimated $1.99M sold.

Readystate Asset Management first reported a position in ALGS in Q1 2025 and held it in 3 quarters. The position peaked at $1.99M in Q3 2025. 40 funds tracked by Wall St. Rank hold ALGS as of Q4 2025.

  • Readystate Asset Management reported no remaining Aligos Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Readystate Asset Management sold 203,113 Aligos Therapeutics shares in Q4 2025, an estimated $1.99M.
  • Readystate Asset Management first reported a position in Aligos Therapeutics in Q1 2025 and held it in 3 quarters.
  • Readystate Asset Management's Aligos Therapeutics position peaked at $1.99M in Q3 2025.
  • 40 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q4 2025.

Based on Readystate Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.